Viking Therapeutics’ $575 Million Raise Gives Its Obesity Ambitions New Muscle -( $VKTX $IBB $XBI )

With oral VK2735 entering Phase 3 and injectable trials fully enrolled, Viking Therapeutics (NASDAQ: VKTX) is building a broader case in weight management.

Viking Therapeutics (NASDAQ: VKTX) has strengthened two foundations of its obesity-drug investment story: the capital to advance its programs and a clinical strategy that increasingly extends beyond a single weekly injection. The company closed financing transactions generating approximately $575 million in gross proceeds in September, then announced the start of its Phase 3 oral VK2735 program in October. Together, those developments give many a more substantial proposition to evaluate: an obesity-drug developer pursuing injectable treatment, oral treatment and long-term maintenance options. The bullish argument rests on optionality. If VK2735 succeeds in larger, longer studies, Viking could offer different ways to begin treatment and sustain weight loss. That remains a clinical and commercial ambition, not an established outcome. But it is an ambition backed by fresh financing and multiple late-stage trials. In biotechnology, a promising molecule attracts attention. A promising molecule with money for the next round of experiments tends to keep it.

A $575 Million Financing Adds Financial Firepower

On September 28, Viking announced the closing of concurrent offerings comprising 9,035,714 common shares at $35 each and $258.75 million in principal amount of 2.00% convertible senior notes due in 2032. Underwriters exercised their options to purchase additional shares and notes in full. Estimated combined net proceeds were approximately $547.8 million after underwriting discounts, commissions and offering expenses. Management intends to direct the proceeds toward continued development, advancement and potential commercialization of VK2735, development of its VK3019 program, and broader research, working capital and corporate needs. The financing therefore supports more than another clinical headline. It adds resources for the expensive progression from encouraging results toward potential regulatory submissions and commercial preparation. The convertible notes carry an initial conversion price of approximately $50.75 per share, compared with the equity offering price of $35. Viking may settle conversions in cash, stock or a combination, subject to the transaction’s terms. That conversion price is a financing provision, not a price target or a promise about where VKTX shares will trade. There is an unavoidable trade-off. The common-stock issuance dilutes existing holders, while the notes add debt and potential future dilution. The positive interpretation is that Viking has exchanged some ownership dilution for greater financial capacity to advance its pipeline. Whether that exchange creates lasting shareholder value will depend on clinical execution.

Oral VK2735 Enters Phase 3, Expanding the Investment Case

Viking’s October 14 announcement moved the oral formulation of VK2735 into the SUNRISE Phase 3 program. VK2735 activates both the GLP-1 and GIP receptors, making it a dual agonist under development for obesity in tablet and injectable formulations. The oral program consists of two randomized, double-blind, placebo-controlled studies:

• SUNRISE-1 targets approximately 560 adults with obesity, or overweight with at least one weight-related condition, without type 2 diabetes.
• SUNRISE-2 targets approximately 560 adults with type 2 diabetes who have obesity or are overweight.
• Both studies will evaluate once-daily doses of 27.5 mg, 35 mg and 55 mg against placebo over 68 weeks, with percentage change in body weight as the primary endpoint.

For many, the significance is broader than the arrival of another trial acronym. Viking is testing whether its molecule can support a second delivery format with potential relevance to both initial weight reduction and ongoing management. A tablet could appeal to patients who prefer to avoid injections. It could also give clinicians another treatment option. Neither preference nor convenience, however, automatically translates into better adherence or commercial success. Those benefits remain to be demonstrated for oral VK2735. The opportunity is meaningful precisely because the question is still open.

The Phase 2 Results Explain the Enthusiasm, and the Scrutiny

Viking’s earlier VENTURE-Oral study provides the clinical foundation for the Phase 3 effort. In the 13-week Phase 2 trial, patients receiving oral VK2735 achieved mean weight reductions from baseline of up to 12.2%. The company reported progressive weight loss without evidence of a plateau over the study period. At the strongest reported response levels, up to 97% of treated patients achieved at least 5% weight loss and up to 80% achieved at least 10%, compared with 10% and 5%, respectively, among placebo recipients. These are “up to” results across treatment groups, not outcomes achieved uniformly by every dose or participant. Those findings give Viking a credible reason to pursue longer studies. They do not establish how much weight patients will lose over 68 weeks, whether results will be durable, or how VK2735 compares with other drugs in a head-to-head setting. Tolerability deserves equal billing. Viking’s Phase 2 announcement reported adverse-event-related treatment discontinuation in 20% of VK2735 recipients, compared with 13% of placebo recipients. Overall treatment discontinuation was 28% and 18%, respectively. Gastrointestinal adverse events were the most common reasons for stopping treatment. A bullish reading should not hide those figures. Rather, it should recognize that Phase 3 must establish a persuasive balance between weight reduction and patients’ ability to remain on therapy. The scale may deliver the headline. Staying on treatment helps determine the business.

Injectable VK2735 Gives Viking a Second Late-Stage Track

The oral program is not Viking’s only route toward a potential obesity franchise. The company’s injectable VANQUISH program comprises two Phase 3 studies evaluating weekly subcutaneous VK2735 over 78 weeks. VANQUISH-1 is fully enrolled with approximately 4,500 adults without type 2 diabetes, while VANQUISH-2 is fully enrolled with approximately 1,000 adults with type 2 diabetes. Both compare weekly doses of 7.5 mg, 12.5 mg and 17.5 mg with placebo. The injectable program follows Phase 2 findings showing mean weight reductions from baseline of up to 14.7% after 13 weeks, with no signs of a plateau during that study. As with the oral results, these shorter-term findings provide a rationale for further development rather than a guarantee of Phase 3 success. Having both formulations in late-stage development broadens Viking’s strategic possibilities. Successful programs could support different patient preferences and treatment approaches. But they are not independent bets: both formulations depend on VK2735, so important molecule-specific safety or efficacy findings could influence the wider investment thesis. For shareholders, that is a useful distinction between multiple opportunities and complete diversification.

Maintenance Dosing Could Be Viking’s Most Interesting Strategic Angle

Obesity treatment is not simply a contest to produce the largest initial percentage reduction. Maintaining that reduction matters. The peer-reviewed SURMOUNT-4 trial illustrates the challenge. After an initial 36 weeks of tirzepatide treatment, participants randomized to placebo experienced a mean 14.0% increase in weight over the following 52 weeks, measured from randomization. Those continuing tirzepatide experienced an additional 5.5% reduction. The findings support the importance of sustained treatment for many patients rather than a short course followed by a permanent farewell. Viking is pursuing that longer-term question directly. Reuters reported in September that participants switched to every-other-week VK2735 injections retained up to 97% of their previously achieved weight loss during a 12-week maintenance period. Those switched to monthly injections retained up to 90%. These percentages describe the proportion of earlier weight loss retained, not the percentage of starting body weight lost. The early results suggest a potentially useful direction, but the maintenance period was short. Longer follow-up will be necessary to establish durability and safety. Viking subsequently announced another maintenance study involving approximately 195 adults. Importantly, its October 14 release corrected the earlier description of the dosing options: the study evaluates daily oral doses, monthly injections, every-other-week injections or placebo, not weekly oral dosing.[finance.yahoo][ir.vikingtherapeutics]

If supported by further evidence, a treatment approach that moves patients from initial weight loss into a convenient maintenance regimen could become an important differentiator. The commercial appeal would be straightforward: helping patients preserve progress without making treatment unnecessarily burdensome.

That is a hypothesis worth testing, not yet a product claim.

A Large Medical Need Leaves Room for Better Treatment Options

Viking is developing its programs against a substantial global disease burden. The World Health Organization estimates that 2.6 billion adults were overweight in 2024, including approximately 940 million living with obesity.[who]

Those figures establish the scale of the health problem. They should not be mistaken for Viking’s addressable paying market. Approval, prescribing practices, insurance coverage, pricing, manufacturing capacity and competition will determine how much of the broader need becomes a commercial opportunity.

The investment case therefore does not require a heroic assumption that every eligible patient becomes a customer. It requires Viking to demonstrate a clinically useful product with a defensible place in treatment.

The company’s pursuit of oral, injectable and maintenance approaches gives it several ways to attempt that. It does not eliminate the need to prove each one.[finance.yahoo][ir.vikingtherapeutics][reuters]

What Investors Should Watch Next

The next stage of the VKTX story should be judged by evidence rather than the enthusiasm of the adjectives surrounding it.

The most important questions include:

• Can the oral SUNRISE program reproduce meaningful weight loss over 68 weeks while establishing an acceptable safety and tolerability profile?[finance.yahoo][ir.vikingtherapeutics]
• Can the 78-week VANQUISH studies validate the injectable formulation in much larger patient populations, both with and without type 2 diabetes?[ir.vikingtherapeutics]
• Can maintenance studies demonstrate that less frequent injections or daily tablets preserve weight loss beyond a short observation period?[ir.vikingtherapeutics][reuters]
• Can Viking translate approximately $547.8 million in new net financing proceeds into clinical progress without an unfavorable increase in spending or further financing requirements? The proceeds are disclosed, but they do not by themselves establish a specific cash runway.[finance.yahoo]
• If development succeeds, can the company establish manufacturing, access and commercial execution sufficient to turn clinical results into a durable business?

These are substantial hurdles. They are also the milestones through which a development-stage biotechnology company can earn a more valuable position.

The Case: A Broader Obesity Platform Is Taking Shape

Viking’s strongest investment argument is not that approval is assured or that its early results establish superiority. Neither claim is supported. It is that the company has combined additional financing with a broader late-stage development strategy. Injectable VK2735 is being evaluated in fully enrolled Phase 3 trials. Oral VK2735 has entered its own Phase 3 program. Maintenance studies are exploring how the molecule might fit into longer-term care. That combination gives investors a more substantive thesis than a single promising data release: Viking is attempting to build a flexible obesity-treatment offering around one molecule, with multiple ways to administer it and potentially sustain its benefits. Success still depends on the data. But with the financing completed and the clinical program expanding, Viking has given its ambitions more room to run. In biotechnology, optimism is easy to issue. Funding the work required to justify it is the more interesting announcement.

The Sources

1. Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
   https://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-closing-concurrent-203000029.html
2. Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
   https://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-initiation-vk2735-110500119.html
3. Viking Therapeutics Convertible Note Offering: SEC Free Writing Prospectus
   https://www.sec.gov/Archives/edgar/data/1607678/000121390026102798/ea0306515-fwp_viking.htm
4. Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
   https://ir.vikingtherapeutics.com/2026-09-24-Viking-Therapeutics-Prices-Upsized-500-Million-Offering-of-Common-Stock-and-Convertible-Senior-Notes
5. Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
   https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity
6. Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding VENTURE-Oral Study
   https://vikingtherapeutics.com/wp-content/uploads/2026/05/Treatment-with-Oral-VK2735-Results-in-Significant-Weight-Loss-The-Randomized-Placebo-Controlled-Dose-Finding-VENTURE-Oral-Study.pdf
7. Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
   https://ir.vikingtherapeutics.com/2026-03-26-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-VANQUISH-2-Trial-of-VK2735
8. Viking Therapeutics’ Obesity Drug Shows Durable Weight-Loss Maintenance
   https://www.reuters.com/business/healthcare-pharmaceuticals/viking-therapeutics-obesity-drug-shows-22-weight-loss-study-2026-09-22/
9. Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
   https://ir.vikingtherapeutics.com/2026-10-06-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity
10. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2812936
11. Obesity and Overweight
    https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight